ESR1 and breast carcinoma: Previous studies demonstrated that MRPL15 is significantly associated with poor prognosis of patients with breast cancer and that it can be used with other MRPs to establish a model to predict the prognosis of and drug efficacy for patients with estrogen receptor‐positive breast cancer.32